In the latest session, BioAtla Inc (NASDAQ: BCAB) closed at $2.86 down -8.63% from its previous closing price of $3.13. On the day, 598121 shares were traded.
Ratios:
For a deeper understanding of BioAtla Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.11 and its Current Ratio is at 4.11. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on September 15, 2022, initiated with a Mkt Outperform rating and assigned the stock a target price of $17.
On May 05, 2022, Credit Suisse Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $35 to $5.
On March 21, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $25.H.C. Wainwright initiated its Buy rating on March 21, 2022, with a $25 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 26 ’23 when MCBRINN SYLVIA bought 4,000 shares for $2.33 per share. The transaction valued at 9,320 led to the insider holds 15,125 shares of the business.
SHORT JAY M PHD bought 50,000 shares of BCAB for $106,910 on Dec 20 ’23. The Chief Executive Officer now owns 1,439,283 shares after completing the transaction at $2.14 per share. On Dec 19 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 20,000 shares for $2.05 each. As a result, the insider paid 41,048 and bolstered with 38,459 shares of the company.
Stock Price History:
Over the past 52 weeks, BCAB has reached a high of $4.07, while it has fallen to a 52-week low of $1.24.
Shares Statistics:
A total of 48.08M shares are outstanding, with a floating share count of 38.77M. Insiders hold about 19.40% of the company’s shares, while institutions hold 54.69% stake in the company.
Earnings Estimates
There are BioAtla, Inc. different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $0.77, with high estimates of $10.77 and low estimates of $15.50.
Analysts are recommending an EPS of between $Financial Services and $Financial Services for the fiscal current year, implying an average EPS of $Technology.
